Development of treatment technology for COVID-19-associated pneumonia with drugs containing quercetin flavonoid

Development of new methods and approaches to the treatment of COVID-19 with known drugs, namely, using bioflavonoid quercetin is pathogenetically proved and perspective. The work aimed to study the effect of drugs containing quercetin on the course of coronavirus-associated pneumonia on the background of basic therapy. This clinical trial was conducted and involves a total of 200 patients, male and female, aged >18 years old, with pneumonia associated with 2019-nCoV acute respiratory disease, who were treated as inpatients and received basic therapy. The results of the controlled trial indicate that staged therapy with quercetin (staged administration of Corvitin^® and Quertin) against baseline therapy accelerates recovery by 2 days in patients with coronavirus-associated pneumonia compared to the control group. The results of the controlled trial confirm the high level of safety of the used quercetin regimen.

References:

1. http://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—27-april-2021
2. http://www.who.int/publications/m/item/weekly-operational-update-on-covid-19—28-june-2021
3. Yang Y., Islam M.S., Wang J. et al. (2020) Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective. Internat. J. Biol. Sci., 16(10): 1708–1717.
4. Y. Li (2016) Quercetin, inflammation and immunity. Nutrients, 167(8): 1–14.
5. Zhang M. (2011) Antioxidant Properties of Quercetin. Oxygen Transport to Tissue XXXII. Vol. 701. Boston, MA, Springer US, 283–289 p. doi.org/10.1007/978-1-4419-7756-4_38.
6. Ozgen S., Kilinc O.K., Selamoğlu Z. (2016) Antioxidant Activity of Quercetin: A Mechanistic Review. Turk. J. Agricult. Food Sci. Technol, 4(12): 1134–1138. doi. org/10.24925/turjaf.v4i12.1134-1138.1069
7. Xiao X. (2011) Quercetin Suppresses Cyclooxygenase-2 Expression and Angiogenesis through Inactivation of P300 Signaling. PLOS ONE, 6(8): e22934. doi.org/10.1371/journal.pone.0022934
8. Alrawaiq N.S. (2014) A Review of Flavonoid Quercetin: Metabolism, Bioactivity and Antioxidant Properties. Intern. J. Pharm. Tech. Res., 6(3): 933–941.
9. Kumar R. (2017) Health Benefits of Quercetin. Defence Life Sci. J., 2(2): 142–151.
10. Fortunato L.R. (2012) Quercetin: a flavonoid with the potential to treat asthma. Brazilian J. Pharm. Sci., 48(4): 590–598.
11. Bischoff S.C. (2008) Quercetin: potentials in the prevention and therapy of disease. Curr. Opin. Clin. Nutr. Metab. Care, 11(6): 733–740.
12. Jin H.B., Yang Y.B., Song Y.L. et al. (2012) Protective roles of quercetin in acute myocardial ischemia and reperfusion injury in rats. Mol. Biol. Rep., 39: 11005–11009.
13. Bartekova M., Carnicka S., Pancza D. et al. (2010) Acute treatment with polyphenol quercetin improves postischemic recovery of isolated perfused rat hearts after global ischemia. Can. J. Physiol. Pharmacol., 88: 465–471.
14. Wang Y., Zhang Z.Z., Wu Y. et al. (2013) Quercetin postconditioning attenuates myocardial ischemia/reperfusion injury in rats through the PI3K/Akt pathway. Braz. J. Med. Biol. Res., 46(10): 861–867.
15. Maksyutina N.P. (2012) Bioflavonoids as organoprotection drugs: Quercetin, Corvitin, Quvertin: Monograph. Scientific opinion, Kiev, 274 p. (In Rus.).
16. Peiris J.S., Lai S.T., Poon L.L. et al. (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet, 361: 1319–1325.
17. Liang T. (Ed.) (2020) Handbook of COVID-19 Prevention and Treatment. Zhejiang University School of Medicine, 60 p.
18. Marik P. (2020) EVMS critical care COVID-19 management protocol (http://www.evms.edu/media/ evms_public/departments/internal_medicine/EVMS_Critical_Care_ COVID-19_Protocol.pdf).
19. Parkhomenko A.N., Kozhukhov S.N. (2014) Results of an open randomized study to study the tolerability and efficacy of Corvitin® in patients with congestive heart failure and left ventricular systolic dysfunction. UMJ, 4: 71–76. (In Rus.).
20. Moibenko A.A., Parkhomenko A.N., Kozhukhov S.N. (2003) The efficacy of a water-soluble form of quercetin (corvitin) in the treatment of acute coronary syndrome with ST segment elevation. NAMS of Ukraine J., 9(2): 361–370. (In Rus.).
21. Parkhomenko A.N., Kozhukhov S.N. (2005) The efficacy of the intravenous form of quercetin 5-lipoxygenase blocker in patients with myocardial infarction and acute heart failure syndrome: a possible connection with the correction of nitric oxide metabolism. UMJ, 5: 45–51. (In Rus.).
22. Parkhomenko A.N., Kozhukhov S.N., Moibenko A.A., Gavrilenko T.I. (2008) Corvitin 5-lipoxygenase blocker: influence on markers of inflammation and endothelial dysfunction in patients with acute myocardial infarction. Ration. Pharmacoter., 2(1): 85–88. (In Rus.).
23. Moibenko A.A., Dosenko V.E., Parkhomenko A.N. (2008) Endogenous mechanisms of cardioprotection as the basis for pathogenetic therapy of heart diseases. Sci. Opin., Kyiv, 518 p. (In Rus.).
24. Parkhomenko A.N., Kozhukhov S.N. (2009) Prospective Registry of Acute Decompensated Heart Failure: One Center Experience. UMJ, 4(72): 10–13. (In Rus.).
25. Gaponova T.I., Kobelyatskiy Yu.Yu., Panchenko G.V. (2015) The role of corvitin and latrene in the prevention and treatment of reperfusion syndrome during reconstructive surgery in patients with chronic lower limb ischemia. Int. Care Med., 2(65) (In Rus.).
26. Alyavi A.L., Kenzhaev M.L., Alyavi B.A. (2009) The effect of corvitin on reversible left ventricular myocardial dysfunction in patients with acute coronary syndrome with ST segment elevation. Practice. angiol., 1(20) (In Rus.).
27. Chornomidz I.B. (2011) Clinical and pathogenetic substantiation of quercitin use in complex treatment of children with acute community-acquired pneumonia. Bull. Sci. Res., 1: 34–36. (In Ukr.).
28. Fedortsiv O.E., Chornomidz I.B., Begosh N.B. (2013) Clinical efficacy of quercetin in the treatment of children with community-acquired pneumonia. Act. Probl. Pediatr. Obstetr. Gynecol., 2: 7–9. (In Ukr.).
29. Zupanets I.A., Pidpruzhnykov Y.V., Sabko V.E. et al. (2019) UPLC-MS/MS quantification of quercetin in plasma and urine following parenteral administration. Clin. Phytosci., 5: 11.